These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8955759)

  • 1. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis.
    Küchle C; Fricke H; Held E; Schiffl H
    Am J Nephrol; 1996; 16(6):484-8. PubMed ID: 8955759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dialysis-associated amyloidosis.
    Sethi D
    Ren Fail; 1993; 15(3):349-51. PubMed ID: 8516489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients.
    Schiffl H
    Hemodial Int; 2014 Jan; 18(1):136-41. PubMed ID: 23718290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach.
    Cianciolo G; Colí L; La Manna G; Donati G; D'Addio F; Comai G; Ricci D; Dormi A; Wratten M; Feliciangeli G; Stefoni S
    Int J Artif Organs; 2007 Oct; 30(10):864-78. PubMed ID: 17992647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes.
    Campistol JM; Torregrosa JV; Ponz E; Fenollosa B
    Contrib Nephrol; 1999; 125():76-85. PubMed ID: 9895432
    [No Abstract]   [Full Text] [Related]  

  • 6. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes.
    Degiannis D; Czarnecki M; Donati D; Homer L; Eisinger RP; Raska K; Raskova J
    Am J Nephrol; 1990; 10(4):276-82. PubMed ID: 2240054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of reprocessing cuprophane and polysulfone dialyzers on beta 2-microglobulin removal from hemodialysis patients.
    Petersen J; Moore RM; Kaczmarek RG; Singh B; Yeh I; Hamburger S; Kankam M
    Am J Kidney Dis; 1991 Feb; 17(2):174-8. PubMed ID: 1992659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new polyamide membrane (Polyflux 130) in high-flux dialysis.
    Schaefer RM; Gilge U; Goehl H; Heidland A
    Blood Purif; 1990; 8(1):23-31. PubMed ID: 2198889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of beta 2-microglobulin by hemodialysis and hemofiltration: a four year follow up.
    Schiffl H; D'Agostini B; Held E
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1223-32. PubMed ID: 1457695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical background and clinical treatment of dialysis-related amyloidosis.
    Yamamoto S; Gejyo F
    Biochim Biophys Acta; 2005 Nov; 1753(1):4-10. PubMed ID: 16226497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte, platelet and endothelial activation in patients with acute renal failure treated by intermittent hemodialysis.
    de Sá HM; Freitas LA; Alves VC; Garção MF; Rosa MA; Marques AA
    Am J Nephrol; 2001; 21(4):264-73. PubMed ID: 11509797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dialysis-related amyloidosis: history and clinical manifestations.
    Danesh F; Ho LT
    Semin Dial; 2001; 14(2):80-5. PubMed ID: 11264771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group.
    Locatelli F; Mastrangelo F; Redaelli B; Ronco C; Marcelli D; La Greca G; Orlandini G
    Kidney Int; 1996 Oct; 50(4):1293-302. PubMed ID: 8887291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization of Dicea a new cellulose membrane for haemodialysis.
    Hoenich NA; Woffindin C; Cox PJ; Goldfinch M; Roberts SJ
    Clin Nephrol; 1997 Oct; 48(4):253-9. PubMed ID: 9352161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis.
    van Ypersele de Strihou C; Jadoul M; Malghem J; Maldague B; Jamart J
    Kidney Int; 1991 May; 39(5):1012-9. PubMed ID: 2067196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-2-microglobulin-associated amyloidosis in chronic hemodialysis patients with carpal tunnel syndrome.
    Ullian ME; Hammond WS; Alfrey AC; Schultz A; Molitoris BA
    Medicine (Baltimore); 1989 Mar; 68(2):107-15. PubMed ID: 2646507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carpal cysts in hemodialysis patients].
    Viglietta G; Pavlica P; Dalla Rovere S; Santoro A; Spongano M; Ferrari G
    Radiol Med; 1989 Oct; 78(4):305-10. PubMed ID: 2687960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Beta 2-microglobulin and dialysis-related amyloidosis].
    Gejyo F
    Rinsho Byori; 2001 Mar; 49(3):244-8. PubMed ID: 11307323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux.
    Schiffl H; Fischer R; Lang SM; Mangel E
    Nephrol Dial Transplant; 2000 Jun; 15(6):840-5. PubMed ID: 10831638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.